苏州高迈药业

Suzhou Gaomai Pharmaceutical is a clinical-stage biopharmaceutical company headquartered in Suzhou, China, dedicated to developing innovative therapies for metabolic diseases. The company focuses on high-impact targets such as the thyroid hormone receptor beta (THR-β) and incretin receptors to treat conditions like metabolic dysfunction-associated steatohepatitis (MASH), obesity, and diabetes. Its lead candidate, GM-H-01, is a selective THR-β agonist currently undergoing clinical evaluation for the treatment of MASH. Gaomai Pharma aims to provide next-generation small molecule treatments with optimized pharmacological profiles and improved patient compliance. The company is backed by prominent venture capital firms and operates out of the Suzhou Industrial Park biotech hub. Their research strategy emphasizes the discovery of oral small molecules that can match or exceed the efficacy of injectable biologics in the metabolic space.